Trial Profile
A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 04 Oct 2019 Status changed from active, no longer recruiting to completed.
- 31 Jul 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Nov 2016, as reported by ClinicalTrials.gov.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (n = 15).